

4. ERPR + or – HER2 + (adjuvant chemotherapy) v.9-17-19

<p>Pre-Surgical Care</p> <p>Consults</p> <ul style="list-style-type: none"> <input type="checkbox"/> Medical oncology <input type="checkbox"/> Surgical oncology <input type="checkbox"/> Radiation oncology <input type="checkbox"/> Plastic surgery <input type="checkbox"/> General medicine <input type="checkbox"/> Chronic disease management <input type="checkbox"/> Fertility preservation https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (pg.38) <input type="checkbox"/> GYN/birth control https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (pg.38) <input type="checkbox"/> Dental consult <input type="checkbox"/> PT (evaluation & lymphedema teaching) https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf (pg. 75) <input type="checkbox"/> Smoking cessation (early if plastic reconstruction candidate) https://www.nccn.org/professionals/physician_gls/pdf/smoking.pdf <input type="checkbox"/> Genetics <input type="checkbox"/> Distress screen <input type="checkbox"/> Hair loss prevention (particularly in case of non-anthracycline chemotherapy) <input type="checkbox"/> Financial counseling/Insurance prior authorization <input type="checkbox"/> Social work evaluation <input type="checkbox"/> Research <p>Tests/Imaging</p> <ul style="list-style-type: none"> <input type="checkbox"/> MRI breasts https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (pg.37) <input type="checkbox"/> U/S breast/axilla <input type="checkbox"/> Biopsy/clip placement confirmation breast/axilla <input type="checkbox"/> CT PET or CT chest/abdomen and bone scan (clinical stage IIB or III) <p>Definitive Breast Surgery</p> <ul style="list-style-type: none"> <input type="checkbox"/> Axillary surgery, sentinel LN mapping and biopsy or targeted I-125 seed localized lumpectomy (TAD) or formal axillary dissection <input type="checkbox"/> Lumpectomy w/needle localization or seed localization <input type="checkbox"/> Line placement <input type="checkbox"/> Post-op care and activity teaching <input type="checkbox"/> Post-op PT evaluation and lymphedema teaching 	<p>Pre-Adjuvant Chemotherapy https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (pg.48)</p> <ul style="list-style-type: none"> <input type="checkbox"/> Cardiac ECHO or MUGA, baseline, after AC given, and every three months while on anti-HER therapy <input type="checkbox"/> CBC with differential <input type="checkbox"/> CMP with liver panel <input type="checkbox"/> Hepatitis B testing <input type="checkbox"/> FSH/estradiol <input type="checkbox"/> B12 <input type="checkbox"/> Pregnancy test (urine or serum) <input type="checkbox"/> Venous access <input type="checkbox"/> Flu shot <p>Adjuvant Chemotherapy for HER 2 Positive Breast Cancer https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (pg.21)</p> <p>HER+, ER+ or -, Chemotherapy</p> <ul style="list-style-type: none"> <input type="checkbox"/> AC-weekly paclitaxel trastuzumab pertuzumab (tumor>2cm and /or node positive) <input type="checkbox"/> AC-paclitaxel trastuzumab <input type="checkbox"/> Docetaxel carboplatin pertuzumab trastuzumab (tumor > 2cm and/or node positive) <input type="checkbox"/> Docetaxel carboplatin trastuzumab <input type="checkbox"/> Weekly paclitaxel/trastuzumab 12 weeks (ER/PR+cT1-2pN0M0) <input type="checkbox"/> Consider adjuvant neratinib in high risk patients, especially ER+ within 1 year of end of trastuzumab <input type="checkbox"/> Clinical Trial 	<p>Supportive Considerations</p> <ul style="list-style-type: none"> <input type="checkbox"/> Appointment Calendar (list all appointments) <input type="checkbox"/> Medication Calendar (pre-meds with steroids and anti-nausea meds) <input type="checkbox"/> Anti-emetics https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf <input type="checkbox"/> Bowel regimen for constipation <input type="checkbox"/> Mucositis prevention <input type="checkbox"/> Exercise for prevention of fatigue and neuropathy https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf <input type="checkbox"/> Ranitidine or omeprazole <input type="checkbox"/> Dexamethasone (pre-med for all taxane-containing regimens) <p>Radiation Oncology</p> <ul style="list-style-type: none"> <input type="checkbox"/> Baseline arm measurement <input type="checkbox"/> Pregnancy test <input type="checkbox"/> Breath hold teaching if left sided <input type="checkbox"/> CT planning <input type="checkbox"/> Toxicity management teaching <input type="checkbox"/> Radiation therapy start <input type="checkbox"/> Weekly physician visits <input type="checkbox"/> Post radiation therapy visit and teaching <p>Adjuvant Endocrine Therapy (for ERPR +)</p> <ul style="list-style-type: none"> <input type="checkbox"/> Premenopausal: tamoxifen for 10 years, or ovarian ablation and AI for 5 years, or ovarian ablation and tamoxifen for 5 years <input type="checkbox"/> Postmenopausal: tamoxifen for 10 years, aromatase inhibitor for 5 to 10 years or tamoxifen followed by aromatase inhibitor for 5 to 10 years
---	---	---



Survivorship

https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf

- Treatment summary
- Weight control and alcohol counseling
- Exercise
- Psychology and support resources
- Sexual health
- Bone Health
- Lymphedema
- Neuropathy
- Reconstruction
- Breast cancer screening and f/u schedule
- Communication with primary care physician